EuroBiotech: More articles of note

newspapers
Affimed received a payment from Genentech for reaching a preclinical milestone. (Pixabay)

> NeuroVive Pharmaceutical enrolled the first subject in a phase 1a/b trial of KL1333, a modulator of cellular levels of the NAD+ coenzyme. The drug could be used to treat primary genetic mitochondrial disorders. (Statement)

> Shares in Motif Bio rose more than 90% after it revealed it is meeting with the FDA to discuss the complete response letter for antibiotic iclaprim. (Release)

> Cytovation moved its treatment for HPV-induced warts into clinical development. The Norwegian biotech plans to start a second trial in malignant tumors later in the year. (Statement

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.

> Transgene secured a €20 million credit facility from a French bank. The credit extends Transgene’s cash runway out to the middle of next year. (Release—PDF)

> Affimed received a payment from Genentech for reaching a preclinical milestone. (Statement)

> Enterome teamed up with Dana-Farber Cancer Institute to develop microbiome-derived antigens as cancer immunotherapies. The alliance gives Enterome access to the cancer institute’s preclinical models. (Release)